
US stock futures higher ahead of Fed interest rate announcement
US stock futures higher ahead of Fed interest rate announcement
Show Caption
Hide Caption
Trump threatens Iran's leader in bid to halt strikes
President Donald Trump threatened Iran's supreme leader with assassination as he pushed Tehran to end its retaliatory airstrikes on Israel.
U.S. stock futures are higher ahead of the Federal Reserve's interest rate announcement this afternoon.
The Fed is expected to hold rates steady as it continues to observe the effects of President Donald Trump's tariffs. So far, tariffs haven't boosted inflation much and the job market has slowed, but not cratered, giving the Fed time to take a wait-and-see approach to tariffs and now the Israel-Iran conflict.
Since Israel attacked Iran, oil prices have jumped to a near five-month high. Much of the world's oil comes from the Middle East, and if oil prices continue to climb or stay elevated for a while, that could ignite inflation.
Along with the Fed's policy announcement, central bankers will release their economic forecasts. Economists expect the Fed to raises its inflation outlook, lower its economic growth forecast and keep the unemployment rate fairly low. Investors will also be looking to see how many rate cuts the Fed expects to implement this year and next.
At 6:10 a.m. ET, futures linked to the blue-chip Dow rose 0.21%, while broad S&P 500 futures gained 0.27% and tech-laden Nasdaq futures added 0.35%.
Cryptocurrency
The Senate passed to regulate stablecoins, or a type of cryptocurrency designed to maintain a stable price, often by being pegged to a more stable asset like the U.S. dollar.
The Senate's legislation requires dollar-pegged stablecoins to hold dollar-for-dollar reserves in short-term government debt or similar products overseen by state or federal regulators.
The bill now goes to the House, which must decide whether it will take up the bill or negotiate a compromise.
Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@usatoday.com and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
6 minutes ago
- CNBC
Senate battle over energy credits
CNBC's Emily Wilkins joins 'Squawk on the Street' with the latest news on how President Trump's 'Big Beautiful Bill' could impact the energy sector.


Bloomberg
7 minutes ago
- Bloomberg
Road to a $3.7 Trillion Stablecoin Market Is Full of Obstacles
The passage of stablecoin legislation in the US Senate marks a huge leap forward for the potential mainstreaming of cryptocurrencies that track the US dollar one-to-one. Yet there are still big problems to solve before many businesses can capitalize on the opportunities that are arising. Now, stablecoins are taking the leap from their original use as crypto-market poker chips to common mediums of exchange, offering merchants and consumers cheaper and more efficient payments systems.


Business Upturn
8 minutes ago
- Business Upturn
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: Rocket Loss Submission Form CLASS PERIOD: February 27, 2025 to May 26, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket's securities at artificially inflated prices. On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made 'several months' earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred. Following this news, the price of Rocket's common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket's stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day. DEADLINE: August 11, 2025 Shareholders should not delay in registering for this class action. Register your information here: NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of RCKT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 11, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018 Email: [email protected] Phone: (646) 453-8903